Advances in Treatment of Oncologic Disorders: Yearly Pharmacotherapy Review

This activity is for pharmacists and is sponsored by Postgraduate Healthcare Education, LLC (PHE).

There has been no commercial support for this activity.


Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
School of Pharmacy
University of Connecticut

Katherine P. Morgan, PharmD, BCOP, CPP
Department of Pharmacy
University of North Carolina Medical Center
Division of Practice Advancement and Clinical Education
University of North Carolina Eshelman School of Pharmacy


Lisa Holle and Katherine Morgan have no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

The reviewer, Megan May, PharmD,  has no relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.

Susanne Kwas, MSHF, BSN, RN, Mary Camillo, and the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-24-072-H01-P
Credits: 2.0 hours (0.20 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: $7.95
Estimated time to complete activity: 120 minutes


June 11, 2024


June 11, 2027


This accredited activity has been designed for pharmacists.


During the period June 11, 2024, through June 11, 2027, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Grade Exam at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To educate pharmacists about selected important advancements during 2023 in the treatment of patients with solid tumors.


Upon completion of this activity, the participant should be able to:

  • Identify new drugs and their indications that were approved in 2023 for patients with solid tumors.
  • Describe the differences between antibody drug conjugates and monoclonal antibodies.
  • Discuss the advancements in treating breast and prostate cancer during 2023.
  • Recognize the drugs that were either approved or taken off the market based on the accelerated drug approval process or have updated labeling requirements in 2023.


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.

Purchase Options

Single Course
Advances in Treatment of Oncologic Disorders: Yearly Pharmacotherapy Review
Amount to be charged: $7.95
Single Course
PowerPak Pharmacist Premium Course Bundle
Save on the average price per course with 12-month access to a pharmacist course bundle option below.*
Premium Course Bundle
*Credits purchased through premium pharmacist course bundles can only be used for individual courses priced at $7.95 and cannot be used for Live Webinars. Once a course bundle is purchased, access to premium courses will be automatically granted, and your credits will be reduced as they are used. Once all credits are used, premium course access will require payment.